Form 4: Agenus CEO Garo Armen Increases Stake Through Performance Bonus and Stock-Based Salary

Agenus Inc. CEO Garo H. Armen has significantly increased his beneficial ownership of company common stock through a 2024 performance bonus award and by electing to receive his salary in shares.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 61,397 shares of Common Stock on June 18, 2025, as part of his 2024 performance bonus award.
• These shares were valued at $4.47 per share on the issuance date and are fully vested but subject to a 30-day lockup restriction, with 100% of the award released on July 18, 2025.
• Additionally, Mr. Armen acquired 3,436 shares of Common Stock on June 27, 2025, representing his net salary for the pay period ending June 27, 2025, paid in stock in lieu of cash.
• The shares acquired for salary were valued at $4.76 per share, based on the closing price on June 27, 2025, and are fully vested on the date of issuance.
• Following these transactions, Mr. Armen directly beneficially owns 258,842 shares of Common Stock.
• Indirect beneficial ownership includes 31,298 shares held in Dr. Armen's IRA accounts and 28,950 shares held by the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, a General Partnership, for which Dr. Armen disclaims beneficial ownership to the extent of his pecuniary interest in Pixie.

Sentiment

Score: 8

Explanation: The sentiment is positive as the CEO's decision to take salary in stock and the receipt of a performance bonus indicate strong alignment with shareholder interests and confidence in the company's future prospects.

Positives

• The CEO's decision to receive salary in stock, in lieu of cash, demonstrates strong confidence in Agenus's future performance and aligns his interests directly with those of shareholders.
• The issuance of a 2024 performance bonus award in stock indicates the achievement of performance metrics by the executive and the company.

Risks

• The 61,397 shares received as a performance bonus are subject to a 30-day lockup restriction, meaning they cannot be sold until July 18, 2025.

Future Outlook

The 61,397 shares received as a 2024 performance bonus will become fully unrestricted and available for sale on July 18, 2025, following the expiration of a 30-day lockup period.

Management Comments

• Garo H. Armen requested and received approval from the Agenus Inc. Compensation Committee to have his salary paid in stock, in lieu of cash.

Industry Context

The practice of executive compensation through stock awards and stock-in-lieu-of-cash salary payments is a common strategy in the biotechnology and pharmaceutical industries. This approach aims to align the interests of executives with those of shareholders, incentivizing long-term company performance and value creation.

Comparison to Industry Standards

• Stock-based compensation, including performance bonuses and salary paid in shares, is a widely adopted practice among publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• This method is generally viewed as a positive governance practice as it directly ties executive wealth to shareholder returns, fostering a strong alignment of interests.

Corporate Governance

Related Party Transactions

• Garo H. Armen holds 31,298 shares indirectly in his IRA accounts.
• Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT, which holds 23,950 shares of Common Stock.
• Dr. Armen is a general partner in Pixie Partners, a General Partnership, which owns 5,000 shares of Common Stock, though he disclaims beneficial ownership to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders are positively impacted by the CEO's increased direct stake and decision to take salary in stock, as it signals strong management confidence and aligns executive incentives with long-term shareholder value creation.
• Employees may view this as a positive sign of leadership commitment and belief in the company's future.

Next Steps

• The 30-day lockup restriction on the 61,397 performance bonus shares will expire on July 18, 2025, at which point they will be fully released.

Key Dates

Keywords

Agenus, Garo Armen, SEC Form 4, Insider Transaction, Stock Compensation, Executive Compensation, Performance Bonus, Biotechnology, AGEN